iTeos Therapeutics, Inc.
ITOS
$7.77
$0.273.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | 35.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | 35.00M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | -- | 35.00M | -- |
| SG&A Expenses | 10.98M | 11.81M | 12.11M | 12.46M | 12.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.53M | 48.48M | 48.63M | 48.27M | 46.43M |
| Operating Income | -39.53M | -48.48M | -48.63M | -13.27M | -46.43M |
| Income Before Tax | -33.51M | -36.36M | -43.12M | -4.87M | -36.00M |
| Income Tax Expenses | 1.10M | 7.36M | 2.24M | 2.26M | 2.21M |
| Earnings from Continuing Operations | -34.61M | -43.71M | -45.36M | -7.13M | -38.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.61M | -43.71M | -45.36M | -7.13M | -38.22M |
| EBIT | -39.53M | -48.48M | -48.63M | -13.27M | -46.43M |
| EBITDA | -39.20M | -48.16M | -48.32M | -12.96M | -46.13M |
| EPS Basic | -0.80 | -1.01 | -1.05 | -0.18 | -1.07 |
| Normalized Basic EPS | -0.48 | -0.53 | -0.62 | -0.08 | -0.63 |
| EPS Diluted | -0.80 | -1.01 | -1.05 | -0.18 | -1.07 |
| Normalized Diluted EPS | -0.48 | -0.53 | -0.62 | -0.08 | -0.63 |
| Average Basic Shares Outstanding | 43.24M | 43.18M | 43.14M | 39.70M | 35.84M |
| Average Diluted Shares Outstanding | 43.24M | 43.18M | 43.14M | 39.70M | 35.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |